DJIA 17,001.22 -38.27 -0.22%
NASDAQ 4,538.55 6.45 0.14%
S&P 500 1,988.40 -3.97 -0.20%
market minute promo

Revance Therapeutics, Inc (NASDAQ: RVNC)

22.56 -1.17 (-4.93%)

Quote as of


company name or ticker

Recent Quotes

RVNC $22.56 -4.93%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $23.70
Previous Close $23.73
Daily Range $22.36 - $24.27
52-Week Range $21.00 - $39.86
Market Cap $530.0M
P/E Ratio -3.42
Dividend (Yield) $0.00 (0.0%)
Volume 530,392
Average Daily Volume 215,753
Current FY EPS -$3.02

Sector

Industry

Revance Therapeutics, Inc (RVNC) Description

Revance Therapeutics, Inc Website: http://www.revance.com/

News & Commentary Rss Feed

Biotech 101: Valuing Binary Events

Sarepta Therapeutics, Revance Therapeutics, and Cytokinetics saw big moves recently; MannKind and Orexigen could be next.

These 2 Stocks Could Be Winners Because Plenty Of People Want To Look Younger

Revance Therapeutics' (RVNC) CEO Dan Browne on Q2 2014 Results - Earnings Call Transcript

Baron Funds Comments on Revance Therapeutics Inc

US Stock Futures Flat Ahead Of Jobless Claims

This Week in Biotech: Is This the Return of Big M&A?

Merger and acquisition deals and rumors were the talk of the town this week, while three additional clinical and filing updates led to double-digit percentage moves.

Revance Therapeutics (RVNC) Soars: Stock Up 25.8% - Tale of the Tape

Why GW Pharmaceuticals, Revance Therapeutics, and Allergan Are Today's 3 Best Stocks

M&A activity sends the S&P 500 decisively higher as GW Pharmaceuticals, Revance Therapeutics, and Allergan all jump by double digits.

Why Revance Therapeutics Inc. Shares Are Sitting Pretty

Revance shares are looking good after reporting positive phase 1/2 study data on RT002. Find out what investors should do based on this news.

Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Li

Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lines

See More RVNC News...